KNOXVILLE, Tenn.--(BUSINESS WIRE)--Dec 11, 2007 - Provectus Pharmaceuticals, Inc. (OTCBB:PVCT) (http://www.pvct.com) has received a patent in India protecting its lead oncology agent, PV-10, along with a number of related agents. The patent covers injectable and other forms of the drugs, including capsules, tablets, and oral suspensions and solutions. A range of active compounds are protected, each related to the active ingredient in PV-10.
"Obtaining patent protection in India for PV-10 and our additional pipeline products is a major milestone, assuring a viable route to access a market representing roughly one-fifth of the world's population," noted Craig Dees, Ph.D., CEO of Provectus. "Additionally, as the Indian pharmaceutical industry becomes a larger player in the worldwide market, this protection establishes an important right of ownership for products sold or made in India."
Dees Continued: "The Company is seeking protection of its assets in key markets worldwide, and this patent further validates the value of our science and our global intellectual property strategy to build value for our shareholders. As we focus on clinical development of our lead therapeutic products, PV-10 for cancer and PH-10 for dermatology, we believe that aggressively protecting the intellectual assets underlying our technologies will be vital to our eventual marketing success."
No comments:
Post a Comment